Have a feature idea you'd love to see implemented?
Let us know!
ANIK Anika Therapeutics Inc
Price (delayed)
$16.31
Market cap
$238.87M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.65
Enterprise value
$201.74M
Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Anika Therapeutics partners with clinicians to understand what they need
Highlights
Anika Therapeutics's debt has decreased by 7% YoY and by 2.1% QoQ
ANIK's equity is down by 34% year-on-year and by 14% since the previous quarter
The net income has declined by 31% since the previous quarter
Key stats
What are the main financial stats of ANIK
Market
Valuations
Earnings
Shares outstanding
14.65M
Market cap
$238.87M
Enterprise value
$201.74M
Price to book (P/B)
1.34
Price to sales (P/S)
1.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.23
Revenue
$164.17M
Gross profit
$79.76M
Net income
-$97.52M
EBIT
-$97.43M
EBITDA
-$85.39M
Free cash flow
-$808,000
Per share
Balance sheet
Liquidity
EPS
-$6.65
EPS diluted
-$6.65
Free cash flow per share
-$0.05
Book value per share
$12.16
Revenue per share
$11.12
TBVPS
$14.94
Total assets
$231.41M
Total liabilities
$51.54M
Debt
$25.24M
Equity
$179.86M
Working capital
$110.61M
Debt to equity
0.14
Current ratio
5.34
Quick ratio
3.56
Net debt/EBITDA
0.43
Margins
Efficiency
Dividend
EBITDA margin
-52%
Gross margin
48.6%
Net margin
-59.4%
Operating margin
-58.9%
Return on assets
-37.9%
Return on equity
-48.1%
Return on invested capital
-55%
Return on capital employed
-47.3%
Return on sales
-59.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ANIK stock price
How has the Anika Therapeutics stock price performed over time
Intraday
-0.12%
1 week
-4.95%
1 month
-5.06%
1 year
-26.76%
YTD
-28.02%
QTD
-33.97%
Financial performance
How have Anika Therapeutics's revenue and profit performed over time
Revenue
$164.17M
Gross profit
$79.76M
Operating income
-$96.7M
Net income
-$97.52M
Gross margin
48.6%
Net margin
-59.4%
Anika Therapeutics's net margin has decreased by 34% QoQ
The net income has declined by 31% since the previous quarter
Anika Therapeutics's operating margin has decreased by 29% from the previous quarter
Anika Therapeutics's operating income has decreased by 27% from the previous quarter
Growth
What is Anika Therapeutics's growth rate over time
Valuation
What is Anika Therapeutics stock price valuation
P/E
N/A
P/B
1.34
P/S
1.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.23
The company's EPS fell by 31% QoQ
ANIK's equity is down by 34% year-on-year and by 14% since the previous quarter
ANIK's price to book (P/B) is 26% less than its last 4 quarters average of 1.8 and 21% less than its 5-year quarterly average of 1.7
ANIK's P/S is 54% below its 5-year quarterly average of 3.2 and 33% below its last 4 quarters average of 2.2
Efficiency
How efficient is Anika Therapeutics business performance
Anika Therapeutics's ROE has decreased by 46% from the previous quarter
The return on assets has declined by 44% since the previous quarter
The ROIC is down by 31% since the previous quarter
The company's return on sales fell by 29% QoQ
Dividends
What is ANIK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ANIK.
Financial health
How did Anika Therapeutics financials performed over time
The total assets has decreased by 29% YoY and by 12% QoQ
Anika Therapeutics's total liabilities has decreased by 11% YoY
Anika Therapeutics's debt is 86% lower than its equity
The debt to equity is up by 40% year-on-year and by 17% since the previous quarter
ANIK's equity is down by 34% year-on-year and by 14% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.